Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease
Journal of the American Chemical Society2008Vol. 130(14), pp. 4607–4609
Citations Over TimeTop 10% of 2008 papers
Nigel J. Liverton, M. Katharine Holloway, John A. McCauley, Michael T. Rudd, John W. Butcher, Steven S. Carroll, Jillian DiMuzio, Christine Fandozzi, Kevin F. Gilbert, Shi‐Shan Mao, Charles McIntyre, Kevin T. Nguyen, Joseph J. Romano, Mark W. Stahlhut, Bang-Lin Wan, David B. Olsen, Joseph P. Vacca
Abstract
Molecular modeling of inhibitor bound full length HCV NS3/4A protease structures proved to be a valuable tool in the design of a new series of potent NS3 protease inhibitors. Optimization of initial compounds provided 25a. The in vitro activity and selectivity as well as the rat pharmacokinetic profile of 25a compare favorably with the data for other NS3/4A protease inhibitors currently in clinical development for the treatment of HCV.
Related Papers
- → West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy(2012)8 cited
- Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.(2008)
- → Identification of the protease domain in NS3 of hepatitis C virus(1995)38 cited
- → Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity(1996)31 cited
- Clinical application and analysis of hepatitis C virus NS3 antigen detection by ELISA in human serum(2007)